Nova Patents
PL3255061T3

Selective immunodepletion of endogenous stem cell niche for engraftment

Abstract

This record has no abstract on file.

Term

1.1 yearsto projected expiry

Projected expiry 2 November 2027, counted from filing; an application has no term until it is granted.

  1. Priority
  2. Filed
  3. Published
  4. Today
  5. Projected expiry

24 members in 9 offices

This recordMember, by publication datePriority claim

Priority claims13

Priority claims
DocumentOfficeKindDate
85643506United States of AmericaP
85643506United States of AmericaP
07871350European Patent Office (EPO)A
07871350European Patent Office (EPO)A
17168021European Patent Office (EPO)A
2007083529United States of AmericaW
2007083529United States of AmericaW
171680218–––
856435P–––
EP20070871350–––
EP20170168021–––
US20060856435P–––
WO2007US83529–––

Members24

Family members, oldest first
DocumentOfficeKind
WO2008067115A2World Intellectual Property Organization (WIPO)A2
WO2008067115A3World Intellectual Property Organization (WIPO)A3
EP2088864A2European Patent Office (EPO)A2
US2010226927A1United States of AmericaA1
EP2088864A4European Patent Office (EPO)A4
US2017066834A1United States of AmericaA1
EP2088864B1European Patent Office (EPO)B1
DK2088864T3DenmarkT3
ES2642205T3SpainT3
EP3255061A1European Patent Office (EPO)A1
HUE034583T2HungaryT2
US10072091B2United States of AmericaB2
US2018327507A1United States of AmericaA1
EP3255061B1European Patent Office (EPO)B1
PT3255061TPortugalT
SI3255061T1SloveniaT1
ES2882360T3SpainT3
PL3255061T3This recordPolandT3
EP3960764A1European Patent Office (EPO)A1
US2023128340A1United States of AmericaA1
US11905333B2United States of AmericaB2
US2024400709A1United States of AmericaA1
EP2088864B2European Patent Office (EPO)B2
ES2642205T5SpainT5